Electroporation has been used to deliver CRISPR/Cas9 components to edit the HBB gene that causes beta thalassemia in hematopoietic stem cells, as well as to correct a genetic mutation that causes cystic fibrosis in airway epithelial cells (Graham and Hart 2021). Here, HBB is linked to beta thalassemia.